Omalizumab: Anti-IgE Therapy in Allergy

Overview

Journal Curr Allergy Asthma Rep

Specialties Allergy & Immunology
Pulmonary Medicine

Date 2011 Jan 19

PMID 21243454

Citations 18

Authors

Matthias Volkmar Kopp

Affiliations

Soon will be listed here.

Abstract

Omalizumab is a humanized, monoclonal anti-IgE antibody that binds specifically to circulating IgE molecules, thus interrupting the allergic cascade. Omalizumab has been shown to be highly effective in treating children and adults with moderate to severe allergic asthma. Beyond this indication, the mode of action itself suggests that omalizumab is not only an antiasthmatic drug but also a promising therapeutic option for various allergic conditions, including allergic rhinitis, food allergy, urticaria, allergic bronchopulmonary aspergillosis, insect hypersensitivity, and atopic dermatitis. However, data from double-blind, placebo-controlled clinical trials are only available for allergic rhinitis and moderate to severe bronchial asthma. The aim of this review is to discuss the current clinical data as well as possible further indications of omalizumab treatment.

Citing Articles

Severe Asthma or Chronic Obstructive Pulmonary Disease with Eosinophilic Inflammation? From Uncertainty to Remission under Anti IL-5R Therapy.

Oprescu B, Raduna O, Mihaicuta S, Frent S Medicina (Kaunas). 2024; 60(3).

PMID: 38541113 PMC: 10972318. DOI: 10.3390/medicina60030387.

[Biologics for the treatment of severe asthma: Current status report 2023].

Cetin G, Kepil Ozdemir S, Can Bostan O, Oztop N, Celebi Sozener Z, Karakaya G Tuberk Toraks. 2023; 71(2):176-187.

PMID: 37345400 PMC: 10795269. DOI: 10.5578/tt.20239921.

Poly-L-Lysine-Based αGal-Glycoconjugates for Treating Anti-αGal IgE-Mediated Diseases.

Olivera-Ardid S, Bello-Gil D, Tuzikov A, Araujo R, Ferrero-Alves Y, Garcia Figueroa B Front Immunol. 2022; 13:873019.

PMID: 35432370 PMC: 9009260. DOI: 10.3389/fimmu.2022.873019.

Efficacy and Safety of Omalizumab for the Treatment of Severe or Poorly Controlled Allergic Diseases in Children: A Systematic Review and Meta-Analysis.

Liu L, Zhou P, Wang Z, Zhai S, Zhou W Front Pediatr. 2022; 10:851177.

PMID: 35372142 PMC: 8965060. DOI: 10.3389/fped.2022.851177.

Novel Targeted Biological Agents for the Treatment of Atopic Dermatitis.

Yang N, Chen Z, Zhang X, Shi Y BioDrugs. 2021; 35(4):401-415.

PMID: 34213742 DOI: 10.1007/s40259-021-00490-x.

References

Vigo P, Girgis K, Pfuetze B, Critchlow M, Fisher J, Hussain I . Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol. 2006; 55(1):168-70. DOI: 10.1016/j.jaad.2005.12.045. View

Holgate S, Chuchalin A, Hebert J, Lotvall J, Persson G, Chung K . Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy. 2004; 34(4):632-8. DOI: 10.1111/j.1365-2222.2004.1916.x. View

Djukanovic R, Wilson S, Kraft M, Jarjour N, Steel M, Chung K . Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004; 170(6):583-93. DOI: 10.1164/rccm.200312-1651OC. View

Zirbes J, Milla C . Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis. Pediatr Pulmonol. 2008; 43(6):607-10. DOI: 10.1002/ppul.20804. View

Fahy J, Boushey H . Targeting IgE with monoclonal antibodies: the future is now. Clin Exp Allergy. 1998; 28(6):664-7. DOI: 10.1046/j.1365-2222.1998.00290.x. View

Kopp M, Brauburger J, Riedinger F, Beischer D, Ihorst G, Kamin W . The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis. J Allergy Clin Immunol. 2002; 110(5):728-35. DOI: 10.1067/mai.2002.128804. View

Kessel A, Helou W, Bamberger E, Sabo E, Nusem D, Panassof J . Elevated serum total IgE--a potential marker for severe chronic urticaria. Int Arch Allergy Immunol. 2010; 153(3):288-93. DOI: 10.1159/000314370. View

Brinkmann F, Schwerk N, Hansen G, Ballmann M . Steroid dependency despite omalizumab treatment of ABPA in cystic fibrosis. Allergy. 2009; 65(1):134-5. DOI: 10.1111/j.1398-9995.2009.02147.x. View

Casale T, Busse W, Kline J, Ballas Z, Moss M, Townley R . Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2006; 117(1):134-40. DOI: 10.1016/j.jaci.2005.09.036. View

10.

Finn A, Gross G, van Bavel J, Lee T, Windom H, Everhard F . Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol. 2003; 111(2):278-84. DOI: 10.1067/mai.2003.54. View

11.

Magerl M, Staubach P, Altrichter S, Ardelean E, Krause K, Metz M . Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab. J Allergy Clin Immunol. 2010; 126(3):665-6. DOI: 10.1016/j.jaci.2010.05.047. View

12.

MacGlashan Jr D, Bochner B, Adelman D, Jardieu P, Togias A, McKenzie-White J . Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997; 158(3):1438-45. View

13.

Metz M, Altrichter S, Ardelean E, Kessler B, Krause K, Magerl M . Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria. Int Arch Allergy Immunol. 2010; 154(2):177-80. DOI: 10.1159/000320233. View

14.

Krathen R, Hsu S . Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol. 2005; 53(2):338-40. DOI: 10.1016/j.jaad.2005.02.014. View

15.

Kawakami T, Kitaura J . Mast cell survival and activation by IgE in the absence of antigen: a consideration of the biologic mechanisms and relevance. J Immunol. 2005; 175(7):4167-73. PMC: 1415266. DOI: 10.4049/jimmunol.175.7.4167. View

16.

Walker S, Monteil M, Phelan K, Lasserson T, Walters E . Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev. 2006; (2):CD003559. DOI: 10.1002/14651858.CD003559.pub3. View

17.

Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, von Berg A . Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol. 2002; 109(2):274-80. DOI: 10.1067/mai.2002.121949. View

18.

Bullerkotte U, Wieczorek D, Kapp A, Wedi B . Effective treatment of refractory severe heat urticaria with omalizumab. Allergy. 2009; 65(7):931-2. DOI: 10.1111/j.1398-9995.2009.02268.x. View

19.

Kamin W, Kopp M, Erdnuess F, Schauer U, Zielen S, Wahn U . Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. Pediatr Allergy Immunol. 2009; 21(1 Pt 2):e160-5. DOI: 10.1111/j.1399-3038.2009.00900.x. View

20.

Waibel K, Reese D, Hamilton R, Devillez R . Partial improvement of solar urticaria after omalizumab. J Allergy Clin Immunol. 2010; 125(2):490-1. DOI: 10.1016/j.jaci.2009.11.007. View